Metastatic Castration Resistant Prostate Cancer
Role of AVPR1a in metastatic castration resistant prostate cancer
Conor Lynch, PhD (H. Lee Moffitt Cancer Center)
Yehia Daaka, PhD (University of Florida Health Cancer Center)
Kerry Burnstein, PhD (University of Miami Sylvester Cancer Center)
Metastatic castrate resistant prostate cancer (mCRPC) will claim 2,000 Floridian lives in 2016. The disease typically manifests in the skeleton where it produces painful lesions that greatly contribute to patient morbidity. Androgen deprivation therapies have proven efficacious but eventually, prostate cancer (PC) becomes resistant and new therapies for mCRPC are clearly needed. The Burnstein lab at the University of Miami Sylvester Comprehensive Cancer Center, identified that the G protein coupled receptor (GPCR) arginine vasopressin receptor-1a (AVPR1a), plays a key role in the growth of CRPC cells in vitro and in vivo. Consistent with a possible role in advanced disease, AVPR1a is highly expressed in metastatic PC. We plan to evaluate AVPR1a for its potential as a therapeutic target in CRPC. These studies leverage the synergistic expertise of three Florida investigators; Dr. Kerry Burnstein, an expert in field of AR regulation and CRPC experimental therapeutics, Dr. Yehia Daaka at the University of Florida; a leader in the field of GPCR signaling in PC and Dr. Conor Lynch at the Moffitt Cancer Center; an expert on bone metastatic prostate cancer.
Click here to view our research team.